Table 5.
Histo-scoring based on histopathological changes in each study group
| Edema | Congestion | Tissue separation and breakdown | Edema in spiral ganglion cells | Vacuolization in spiral ganglion cells | ||
|---|---|---|---|---|---|---|
| Group I (Control Group) | Day 4 | 0.2±0.44a | 0±00 | 0±00 | 0±00 | 0±00 |
| Day 8 | 0.2±0.44a | 0±00 | 0±00 | 0±00 | 0±00 | |
| Group II (Cisplatin group) | Day 4 | 1.60±0.54a | 1.00±0.70a | 0.20±0.44 | 0±00 | 0±00 |
| Day 8 | 2.60±0.54ab | 2.60±0.54ab | 2.40±0.89ab | 2.20±0.83ab | 2.60±0.54ab | |
| Group III (Cisplatin + Cortexin group) | Day 4 | 1.40±0.54a | 1.20±0.44a | 0.20±0.44 | 0±00 | 0±00 |
| Day 8 | 0.40±0.54c | 0.40±0.54c | 0.20±0.44c | 0.40±0.54c | 0.20±0.44c |
The variables were expressed as mean±standard deviation.
a
Histopathological changes were significantly different in Cisplatin and Cisplatin+Cortexin groups compared to the control group on the 8th day of study, and between Cisplatin and control groups on the 8th day of study (p<0.05).
b
When the values recorded in Cisplatin group on Days 4 and 8 were compared, Day 8 histo-scores were found to be statistically significantly higher (p<0.05).
c
Comparison of Cisplatin+Cortexin and Cisplatin groups on Day 8 indicated significant decrease in histo-scores of Cisplatin+Cortexin group(p<0.05).